BAY 11-7085 (Synonyms: BAY 11-7083)

Name: BAY 11-7085
Brand: MedChemExpress
SKU: HY-10257
Rating: 5.0 (38 reviews)

Cat. No.: HY-10257 Purity: 99.89%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC₅₀ of 10 μM.

For research use only. We do not sell to patients.

BAY 11-7085 Chemical Structure

CAS No. : 196309-76-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 71	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 71	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 26	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 77	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 99	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 165	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 275	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 38 publication(s) in Google Scholar

36 Publications Citing Use of MCE BAY 11-7085

Proliferation Assay

: BAY 11-7085 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2020 Jul 17;16(7):e1008664. [Abstract]; HPB-ATL-T, MT-2, MT-4, TL-Om1 cells were treated with BAY11-7085 (2.5, 5 μM) or DMSO for 24 h. Treatment with BAY11-7085 significantly impairs AHR expression in these four cell lines.

: BAY 11-7085 purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;43(5):1855-1865. [Abstract]; Elevated SOD activity and HO-1 mRNA expression, and reduced CAT activity induced by LPS are inhibited by BAY 11-7085.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC₅₀ of 10 μM^[1].

IC₅₀ & Target^[1]

NF-κB

IκB-α

10 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	EC₅₀	2.6 μM Compound: 1	Cytotoxicity against human A2780 cells co-cultured with human mesothelial cells after 4 hrs by firefly luciferase assay relative to control Cytotoxicity against human A2780 cells co-cultured with human mesothelial cells after 4 hrs by firefly luciferase assay relative to control	[PMID: 25581261]
A2780	IC₅₀	2.6 μM Compound: 1, BAY-117085	Antitumor activity against human A2780 cells co-cultured with mesothelial cell monolayers by firefly luciferase reporter gene assay Antitumor activity against human A2780 cells co-cultured with mesothelial cell monolayers by firefly luciferase reporter gene assay	[PMID: 22326395]
BXPC-3	EC₅₀	3.5 μM Compound: 1	Cytotoxicity against human BxPC3 cells co-cultured with human mesothelial cells after 4 hrs by firefly luciferase assay relative to control Cytotoxicity against human BxPC3 cells co-cultured with human mesothelial cells after 4 hrs by firefly luciferase assay relative to control	[PMID: 25581261]
BXPC-3	IC₅₀	3.7 μM Compound: 1, BAY-117085	Antitumor activity against human BxPC3 cells co-cultured with mesothelial cell monolayers by firefly luciferase reporter gene assay Antitumor activity against human BxPC3 cells co-cultured with mesothelial cell monolayers by firefly luciferase reporter gene assay	[PMID: 22326395]
DBTRG-05MG	IC₅₀	5.53 μM Compound: 49; BAY 11-7085	Cytotoxicity against human DBTRG-05MG cells assessed as inhibition of cell viability incubated for 24 hrs by sulforhodamine B assay Cytotoxicity against human DBTRG-05MG cells assessed as inhibition of cell viability incubated for 24 hrs by sulforhodamine B assay	[PMID: 36332549]
MDA-MB-231	IC₅₀	4.31 μM Compound: 49; BAY 11-7085	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by sulforhodamine B assay	[PMID: 36332549]
SK-OV-3	EC₅₀	5 μM Compound: 1	Cytotoxicity against human SKOV3 cells co-cultured with human mesothelial cells after 4 hrs by firefly luciferase assay relative to control Cytotoxicity against human SKOV3 cells co-cultured with human mesothelial cells after 4 hrs by firefly luciferase assay relative to control	[PMID: 25581261]
SK-OV-3	IC₅₀	7.6 μM Compound: 1, BAY-117085	Antitumor activity against human SKOV3 cells co-cultured with mesothelial cell monolayers by firefly luciferase reporter gene assay Antitumor activity against human SKOV3 cells co-cultured with mesothelial cell monolayers by firefly luciferase reporter gene assay	[PMID: 22326395]

In Vitro

BAY 11-7085 inhibits TNFa-induced surface expression of E-selectin, VCAM-1, and ICAM-1with IC₅₀ values in the range of 5-10 μM. BAY 11-7085 stabilizes IκBα in a dose-dependent manner with an IC₅₀ value of approximately 10 μM. There is a clear correlation between the concentration of drug that stabilized IκBα, the concentration that inhibits nuclear levels of NF-kB, and the concentration that inhibits adhesion molecule expression^[1].
BAY 11-7085 has been shown to inhibit cell proliferation and induce apoptosis of a variety of cells. BAY 11-7085 (ECSCs) significantly inhibits the cell proliferation and DNA synthesis of ovarian endometriotic cyst stromal cells and induces apoptosis and the G0/G1 phase cell cycle arrest of these cells. BAY 11-7085 induces apoptosis of ECSCs by suppressing antiapoptotic proteins, and that caspase-3-, -8-, and -9-mediated cascades are involved in this mechanism^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BAY 11-7085 acts as an anti-inflammatory agent in both the rat carrageenan paw and the rat adjuvant arthritis model. It demonstrates a dose-dependent reduction in swelling in the rat carrageenan paw model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

249.33

Formula

C₁₃H₁₅NO₂S

CAS No.

196309-76-9

Appearance

Solid

Color

White to off-white

SMILES

N#C/C=C/S(C(C=C1)=CC=C1C(C)(C)C)(=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 26 mg/mL (104.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0107 mL	20.0537 mL	40.1075 mL
5 mM	0.8021 mL	4.0107 mL	8.0215 mL
10 mM	0.4011 mL	2.0054 mL	4.0107 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.99%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (248 KB) LCMS (150 KB)

Handling Instructions (2659 KB)

References

[1]. Pierce JW, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesionmolecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997 Aug 22;272(34):21096-103. [Content Brief]

[2]. Nasu K, et al. Application of the nuclear factor-kappaB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E16-23. [Content Brief]

Cell Assay ^[2]	ECSCs cells are incubated for 48 h with BAY 11-7085 (0.01-10 μM). Thereafter, 20 μL of WST-1 dye are added to each well, and the cells are further incubated for 4 h. All experiments are performed in the presence of 10% FBS. Cell proliferation is evaluated by measuring absorbance at 540 nm^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Rats: 1% suspension of carrageenan in distilled water is administered to rats as 0.1 mL subplantar injection into the footpad of the right hind paw. One hour prior to injection, rats are treated intraperitoneally with vehicle (polyethylglycol 400 diluted 1:5 in 5% bovine serum albumin/water) or a fine suspension of compound 2 (1, 5, or 50 mg/kg) in vehicle. A positive control group is also included in which rats are pretreated with 20 mg/kg ibuprofen. Four hours after carrageenan administration, the volume of the injected paw is measured. Edema volumes are determined^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Pierce JW, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesionmolecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997 Aug 22;272(34):21096-103. [Content Brief] [2]. Nasu K, et al. Application of the nuclear factor-kappaB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E16-23. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.0107 mL	20.0537 mL	40.1075 mL	100.2687 mL
	5 mM	0.8021 mL	4.0107 mL	8.0215 mL	20.0537 mL
	10 mM	0.4011 mL	2.0054 mL	4.0107 mL	10.0269 mL
	15 mM	0.2674 mL	1.3369 mL	2.6738 mL	6.6846 mL
	20 mM	0.2005 mL	1.0027 mL	2.0054 mL	5.0134 mL
	25 mM	0.1604 mL	0.8021 mL	1.6043 mL	4.0107 mL
	30 mM	0.1337 mL	0.6685 mL	1.3369 mL	3.3423 mL
	40 mM	0.1003 mL	0.5013 mL	1.0027 mL	2.5067 mL
	50 mM	0.0802 mL	0.4011 mL	0.8021 mL	2.0054 mL
	60 mM	0.0668 mL	0.3342 mL	0.6685 mL	1.6711 mL
	80 mM	0.0501 mL	0.2507 mL	0.5013 mL	1.2534 mL
	100 mM	0.0401 mL	0.2005 mL	0.4011 mL	1.0027 mL

BAY 11-7085 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BAY 11-7085196309-76-9BAY 11-7083NF-κBFerroptosisApoptosisNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

BAY 11-7085 (Synonyms: BAY 11-7083)

Customer Review

BAY 11-7085 Related Antibodies

36 Publications Citing Use of MCE BAY 11-7085

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

BAY 11-7085 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BAY 11-7085 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report